A patient pulled out her phone in clinic a few weeks ago and showed me a news story about a new pain pill. She wanted to know if she could take that instead of a narcotic after her knee replacement. Some version of that question now comes up almost every week.
Journavx pain medication is what she was reading about. Journavx® is the brand name for a drug called suzetrigine, and it is the first truly new kind of pain medicine we have been given in a very long time. Earlier this year I hosted a podcast conversation about it for the American Association of Hip and Knee Surgeons, so I have spent more time inside this data than most surgeons have.
Here is what I tell patients about it, including the parts that are still unknown.
What Is Journavx Pain Medication?
Journavx pain medication is an oral tablet that treats moderate to severe short-term pain in adults without using an opioid. The FDA approved it on January 30, 2025, and it is made by Vertex Pharmaceuticals.
Short-term pain is what doctors call acute pain: the kind that follows an injury or an operation. It is different from the years of arthritis pain that bring most people to my office.
The tablet comes in a 50 milligram size. The usual plan is one larger starting dose, then a tablet every 12 hours for a short, defined stretch of days.
It is prescription only, approved for adults, and it has not been tested in children.
How Does Journavx Work Without an Opioid?
Journavx works by shutting down a specific gate on your pain nerves before the signal can travel. That gate is a sodium channel called NaV1.8, and it sits almost entirely in the nerves outside your brain and spinal cord.
Think of a pain signal as a phone call. An opioid answers the call in your brain and tells you to ignore it. Journavx cuts the line at the pole outside the house.
That difference is the whole story. Because the drug works out in the peripheral nerves, it does not produce the fog, the euphoria, or the sedation that narcotics do.
The FDA called it first-in-class, which means nothing else on the shelf works this way. Vertex describes it as the first new class of pain medicine approved in more than 20 years, and that framing is fair.
Is Journavx Pain Medication Addictive?
There is no evidence that Journavx is addictive, and the reason is mechanical rather than promotional. The NaV1.8 channel it blocks is not present in the brain in any meaningful amount, so the drug has no route to the reward pathways that make opioids habit forming.
The FDA approved it without the controlled-substance scheduling narcotics carry. I still tell patients that a medicine approved in 2025 has a short safety record compared to drugs we have used for 40 years, and that caveat belongs in the conversation.
What Did the Approval Studies Actually Show?
Two randomized trials earned the approval, and neither involved a joint replacement. One studied pain after a tummy tuck (abdominoplasty), the other pain after bunion surgery (bunionectomy).
In both, patients on Journavx reported meaningfully less pain than patients on a placebo sugar pill. That result was clear and statistically solid.
The second comparison matters just as much. Against a hydrocodone and acetaminophen combination, Journavx was not superior in either trial. It performed comparably.
Read that carefully, because headlines often miss it. This is not a stronger painkiller than a narcotic. It is a similarly effective one with no addiction risk, which is a different and arguably better kind of win.
Safety data came from roughly 874 patients in those trials, plus about 256 more in an open study covering a broader range of painful conditions. That is a solid start, not a decade of experience.
Why Did Journavx Win the 2025 AAHKS Innovation Award?
Vertex received the 2025 Industry Innovation Award at the annual meeting of the American Association of Hip and Knee Surgeons, given each year for work that moves hip and knee surgery forward. I hosted the AAHKS Amplified podcast episode with Jenna Harrington of Vertex to talk through what the drug does and where it might fit.
Hip and knee surgeons care about this for an unglamorous reason. We write a lot of prescriptions for acute pain, and we have spent 15 years trying to write fewer of them for narcotics.
Nearly 10 percent of people given an opioid for short-term pain keep taking opioids longer than intended. Around 85,000 develop an opioid use disorder in a single year. That is why a new mechanism earns an award before the arthroplasty data exists.
Can Journavx Be Used After Hip or Knee Replacement?
Journavx is approved for moderate to severe acute pain of any cause in adults, which includes surgical pain, but it has not been studied specifically in hip or knee replacement patients. I want to be plain about that gap rather than paper over it.
A tummy tuck and a bunion correction are real operations, and they hurt. They are not a total knee replacement, where we cut bone, balance ligaments, and ask you to bend the joint the same afternoon.
Until arthroplasty trials are published, any use after joint replacement is a reasoned extension of the approval, not proof. Some surgeons are already using it that way, and studies are underway.
What I do today is build a layered plan: scheduled acetaminophen, an anti-inflammatory, a nerve block, long-acting numbing medicine in the joint, ice, and early walking. Read more about that nonopioid pain approach and the anesthesia options for hip and knee surgery.
Journavx is a candidate to slot into that plan as evidence grows. It is not a reason to abandon what already works.
What Are the Side Effects and Interactions?
The most common side effects in the trials were itching, muscle spasms, rash, and a rise in a blood muscle enzyme called creatine phosphokinase. Most were mild.
The interactions deserve more attention, and they are the part patients skim past.
- Other prescriptions. Journavx cannot be taken with strong inhibitors of a liver enzyme called CYP3A. A pharmacist can check your list in a minute.
- Grapefruit. None at all while taking it. This one surprises people.
- Hormonal birth control. Some progestin contraceptives are less reliable during treatment and for 28 days afterward. A backup method is needed.
- Liver problems. Reduced liver function may call for a different dose or a different plan.
- Pregnancy and breastfeeding. Safety is not established, so that decision belongs with your own physician.
Who Should Not Take Journavx Pain Medication?
Anyone taking a strong CYP3A inhibitor should not take Journavx pain medication, and that is a rule rather than a caution. Patients with liver disease, patients who are pregnant or nursing, and anyone under 18 need an individual conversation first.
Bring your complete medication list to that conversation, vitamins and herbal supplements included.
What Does Journavx Pain Medication Cost?
Vertex set a list price of $15.50 per 50 milligram tablet, which puts a short course well above the few dollars a generic narcotic costs. That gap is the obstacle I run into most.
Coverage is uneven and still shifting. Some plans pay, some require trying other medicines first, and some do not cover it yet.
Vertex runs patient support programs to help with access. If your surgeon suggests this medicine, ask the office to check coverage before you leave, not at the pharmacy counter.
What I Tell My Patients in Middle Tennessee
I perform more than 700 joint replacements a year and have done this for over 20 years. Pain control is what patients ask about first, ahead of the implant itself, so I take the question seriously when someone drives in from Nashville, Spring Hill, or Columbia.
My read on Journavx pain medication is that it is a real advance and an incomplete one. A drug that relieves pain without touching the brain is exactly what this field needed.
What it has not yet earned is a starring role in total knee replacement or hip replacement recovery, because nobody has run that study. I would rather tell you that than sell you something.
If you are weighing surgery and worried about pain, bring the question to your consultation. Ask what the plan is, what happens if it is not enough, and who answers the phone at 9 at night on a Saturday.
You can schedule a consultation with me at the Bone and Joint Institute of Tennessee, 3000 Edward Curd Lane, Franklin, TN 37067, or call (615) 791-2630. Learn more about my practice and training.
Listen to the full AAHKS Amplified episode with Jenna Harrington of Vertex here: Journavx Wins Award at the 2025 AAHKS Annual Meeting.
Want Dr. Calendine’s articles to stand out in your Google and AI search results? Add him as a preferred source (one tap).
Medical disclaimer: This article is for education only and is not medical advice. Journavx is a prescription medicine; decisions about it belong with your own physician or surgeon, who knows your health history and your other medications. Individual results vary. Cory Calendine, MD is a board-certified orthopedic surgeon specializing in hip and knee replacement at the Bone and Joint Institute of Tennessee in Franklin, Tennessee.
References
- U.S. Food and Drug Administration. FDA approves novel non-opioid treatment for moderate to severe acute pain. FDA News Release. January 30, 2025. fda.gov
- Journavx (suzetrigine) tablets, for oral use. Full Prescribing Information. Vertex Pharmaceuticals Incorporated; 2025. accessdata.fda.gov
- Vertex Pharmaceuticals Incorporated. Vertex announces FDA approval of JOURNAVX (suzetrigine), a first-in-class treatment for adults with moderate-to-severe acute pain. Press release. January 30, 2025. news.vrtx.com
- Suzetrigine (Journavx): a sodium channel blocker for acute pain. The Medical Letter on Drugs and Therapeutics. 2025;67(1723):33-35. medicalletter.org
- American Association of Hip and Knee Surgeons. Vertex Pharmaceuticals’ Journavx wins award at 2025 AAHKS Annual Meeting. AAHKS Amplified podcast, hosted by Cory L. Calendine, MD. August 20, 2026. aahks.org
